Genetic Signatures Limited (GSS.AX)
ASX · AUD · Healthcare · Diagnostics & Research
A$0.076 (+1.33%) as of
Key statistics
- Market cap
- 17.26M
- Forward P/E
- -1.69
- EPS (TTM)
- -0.0600
- Dividend yield
- 0.00%
- 52-week range
- 0.0510 – 0.3500
- Beta
- 0.63
- Revenue (TTM)
- 19.33M
- Profit margin
- -72.45%
- Analyst target
- A$0.31
- Volume
- 21.10k
About Genetic Signatures Limited
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Newtown, NSW, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.